Vaxcyte (PCVX)
(Delayed Data from NSDQ)
$42.66 USD
+2.53 (6.30%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $42.60 -0.06 (-0.14%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PCVX 42.66 +2.53(6.30%)
Will PCVX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PCVX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCVX
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
PCVX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
Other News for PCVX
PCVX forms Expansion Breakout on October 3
Is PCVX poised for gains? New Uptrend shows up after rallying 5.39%
Bank of America Securities Keeps Their Buy Rating on Vaxcyte (PCVX)
Is PCVX preparing to trend higher? Upper Bollinger Band Walk shows up after soaring 5.58%
Is PCVX gaining bullish strength? Stochastic Reached Overbought shows up after rising 3.95%